Regulus Therapeutics (NASDAQ:RGLS) Downgraded by Zacks Investment Research to Hold

Regulus Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Regulus Therapeutics Downgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

View More Regulus Therapeutics (NASDAQ:RGLS) Downgraded by Zacks Investment Research to Hold